Alzheimer’s affects over seven million Americans—a number expected to double by 2050. New FDA-approved drugs and early-detection blood tests give families hope, but government red tape still stands in the way. The Market Institute believes patients and doctors—not bureaucrats—should decide when to use lifesaving innovations. Empowering access to modern treatments isn’t just good policy—it’s the compassionate choice.
A new Supreme Court ruling marks another significant step toward reining in the administrative state and restoring constitutional accountability. Writing in RealClearMarkets, Market Institute President Charles Sauer argues that while Trump v. Slaughter strengthens presidential Read more…
The Market Institute has joined the Center for a Free Economy and more than three dozen national organizations in urging Congress to pass the USTRx Act (H.R. 4780), legislation that would help end the unfair Read more…
The healthcare system is often described as broken, but as Charles Sauer explained during a recent event hosted by the Mises Institute, the solutions already exist. The challenge is not creating better models of care—it’s Read more…
A bipartisan effort in Congress seeks to reinforce First Amendment protections by preventing federal officials from pressuring private companies to censor lawful speech. In a new RealClearMarkets column, Market Institute Senior Fellow Norm Singleton examines Read more…
A new opinion piece by Market Institute President Charles Sauer in RealClearMarkets argues that policymakers should resist efforts to ban personalized pricing, warning that government intervention would undermine consumer choice and market efficiency. As retailers Read more…
A newly published paper in The Milbank Quarterly adds to the growing body of evidence that the federal 340B Drug Pricing Program has strayed far from its original purpose, strengthening the case for meaningful congressional Read more…
6151 Fuller Court #8
Alexandria, VA 22310
The Market Institute
info@marketinstitute.org